<DOC>
	<DOCNO>NCT01687309</DOCNO>
	<brief_summary>A study investigate safety , tolerability , pharmacokinetics , pharmacodynamics single repeat dose 800 mg GSK2586184 healthy subject .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Repeat Doses GSK2586184 Effect Food Gender</brief_title>
	<detailed_description>This study healthy volunteer investigate safety , tolerability , pharmacokinetics ( body 's effect drug ) pharmacodynamics ( drug 's effect body ) single repeat dose 800 mg GSK2586184 . The effect food gender pharmacokinetics also investigate follow single dosing . The study make 2 group healthy subject . The first group consist 6 female subject receive single dose 800mg GSK2586184 ( study medication ) 2 seperate session . One session involve female subject take study medication food session involve study medication take without food . The safety tolerability study medication female subject effect food pharmacokinetics study medication investigate . The second group consist 12 healthy male subject participate 2 session . 8 subject receive study medication 4 receive placebo ( dummy medication ) course study . Neither study doctor know one give . Each male subject receive single dose study medication placebo follow 13 day twice daily dose study medication placebo . Each dose take food.The single dose result group subject compare female group investigate effect gender pharmacokinetics . The safety pharmacokinetics repeat dose investigate . The effect repeat dose kidney function immune system also investigate . The study take place SGS Clinical Pharmacology Unit Antwerp , Belgium . A pharmaceutical company , GlaxoSmithKline , funding study .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitor Cohort A : A female subject nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea Cohort B : Male subject female partner childbearing potential must agree contraception method mandate protocol Cohort A : Subjects 18 65 year age inclusive , time signing informed consent Cohort B : Subjects 18 50 year age inclusive , time signing informed consent Normal creatinine clearance value screen ALT , alkaline phosphatase bilirubin â‰¤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Single QTcF &lt; 480 msec BMI within range 18 30.0 kg/m2 ( inclusive ) Subjects must nonsmoker must use nicotinecontaining product . A nonsmoker define individual abstain smoke least 1 year prior screen A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) A positive prestudy drug/alcohol screen A positive test HIV antibody History sensitivity study medication , Intron A recombinant interferon , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol follow use guide : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) The subject unwilling abstain alcohol consumption 48 hr prior dose discharge clinic , 24 hr prior outpatient clinic visit Exposure four new chemical entity within 12 month prior first dose day Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety History malignancy , except adequately treated noninvasive cancer skin ( basal squamous cell ) cervical carcinoma situ ( &gt; 2 yr prior dose ) Where participation study would result donation blood blood product excess 500 mL within 56 day period Subjects history current thyroid disease epilepsy Subjects expose radiation 6 month , ( except Xray/CT examination extremity ) prior first GFR assessment ( Day 2 ) ( cohort B )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>